Lonza’s Synaffix platform is partnering with Qurient Therapeutics to develop a dual-payload antibody-drug conjugate (ADC) targeting solid tumors. This collaboration combines Synaffix’s exatecan-based linker-payload technology with Qurient’s CDK7 inhibitor to deliver two distinct cytotoxic agents, aiming to enhance therapeutic efficacy and overcome resistance. Lonza will manufacture components while Qurient handles R&D, development, and commercialization.